NCT04865315 A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
| NCT ID | NCT04865315 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Maastricht Radiation Oncology |
| Condition | Low-grade Glioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-05-01 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-05-01 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available. To achieve this goal, a broader understanding is needed of the causes of inter-and intratumoral heterogeneity; glioma dedifferentiation and invasion; the major determinants of malignancy and treatment failure in glioma patients. Patient-derived organoid (PDOs) of high-grade gliomas and low-grade gliomas will be used to identify the mechanisms that underlie this malignant behaviour and treatment resistance. This insight may be used to develop patient avatars to simultaneously test multiple new treatment modalities that are predictive for survival and quality of life of glioma patients.
Eligibility Criteria
Inclusion Criteria: * MRI diagnosis of low grade glioma (LGG) or high grade glioma (HGG) * Age 18 years or older * Patient is eligible for a resection of the tumor Exclusion Criteria: * Contra-inidication for neurosurgical resection of the tumor. * Incapacitated patient, unable to give informed consent.
Contact & Investigator
Marc Vooijs, Prof. Dr.
PRINCIPAL INVESTIGATOR
Maastro Radiaton Oncology clinic
Frequently Asked Questions
Who can join the NCT04865315 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Low-grade Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04865315 currently recruiting?
Yes, NCT04865315 is actively recruiting participants. Contact the research team at annika.noordink@maastro.nl for enrollment information.
Where is the NCT04865315 trial being conducted?
This trial is being conducted at Maastricht, Netherlands.
Who is sponsoring the NCT04865315 clinical trial?
NCT04865315 is sponsored by Maastricht Radiation Oncology. The principal investigator is Marc Vooijs, Prof. Dr. at Maastro Radiaton Oncology clinic. The trial plans to enroll 50 participants.